Chemical formula: C₁₆H₁₃N₃O₃ Molecular mass: 295.293 g/mol PubChem compound: 4030
In vitro and in vivo work suggests that mebendazole blocks the uptake of glucose by adult and larval forms of helminths, in a selective and irreversible manner. Inhibition of glucose uptake appears to lead to endogenous depletion of glycogen stores within the helminth. Lack of glycogen leads to decreased formation of ATP and ultrastructural changes in the cells.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| P02CA01 | Mebendazole | P Antiparasitic products, insecticides and repellents → P02 Anthelmintics → P02C Antinematodal agents → P02CA Benzimidazole derivatives |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| VERMOX Tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC |
Mebendazole is an active ingredient of these brands:
Austria (AT)Canada (CA)Estonia (EE)Ireland (IE)Israel (IL)Lithuania (LT)Mexico (MX)
Netherlands (NL)New Zealand (NZ)Nigeria (NG)Poland (PL)Spain (ES)Tunisia (TN)Turkey (TR)Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
